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Abstract
Background: The management of neuropathic pain (NP) is challenging despite it being the recent focus of
extensive research. A number of clinical practice guidelines (CPGs) for the management of NP have been published
worldwide over the past 2 decades. This study aimed to assess the quality of these CPGs.
Methods: We performed a systematic review of published CPGs for the management of NP. Three reviewers
independently assessed the quality of the CPGs using the Appraisal of Guidelines Research and Evaluation II
(AGREE-II) instrument, and recommendations of CPGs were also appraised.
Results: A total of 16 CPGs were included. Thirteen CPGs were developed using an evidence-based approach, and
the remaining CPGs were produced by consensus panels. None of CPGs obtained a score greater than 50 % in all
six AGREE II instrument domains mainly owing to poor performance in the “Applicability” domain. The highest
score of the CPGs was achieved in “Clarity and Presentation” domain, followed by “Scope and Purpose” and
“Editorial Independence” domains, and the lowest scores were found the in “Applicability” domain. The majority of
the CPG recommendations on the management of patients with NP were relatively consistent, especially regarding
the recommendation of stepwise treatment with medication.
Conclusions: Greater efforts are needed not only to improve the quality of development and presentation of the
CPGs, but also to provide more efficacy evidence for the management of patients with NP.
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Background
Clinical practice guidelines (CPGs), defined as “statements
that include recommendations intended to optimize pa-
tient care that are informed by a systematic review of the
evidence and an assessment of the benefits and harms of
alternative care options”, have been expected to facilitate
more consistent, effective and efficient medical practice,
and ultimately improve health outcomes [1, 2]. Many or-
ganizations worldwide have published CPGs on similar
topics in the past several decades, but their quality has
been found to vary highly [3–5]. Therefore, concerns have
risen about the quality of CPGs.
Neuropathic pain (NP), caused by a somatosensory
lesion or various diseases, comprises a wide range of
heterogenous conditions [6]. NP affects millions of
people worldwide, and its estimated prevalence in the
general population is as high as 7–8 % [7, 8]. Generally,
NP is chronic, severe and resistant to over-the-counter
analgesics. Thus, the management of NP is challenging.
To improve the management for NP, the European
federation of Neurological Societies (EFNS) [9–13],
the Canadian Pain Society Special Interest Group on
Neuropathic Pain (NePSIG) [14–16], the Assessment
Committee of the Neuropathic Pain Special Interest
Group of the International Association for the Study of
Pain (IASP) [17–19], the National Institute for Health and
Care Excellence (NICE) [20, 21], as well as an expert panel
of the Middle East region (MER) [22], Latin American* Correspondence: liujin7710@hotmail.com2Department of Anesthesiology, Translational Neuroscience Center, West
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(LA) [23], and South Africa (SA) [24], have developed the
CPG for the management of NP.
In the present study, we systematically reviewed the
available CPGs for NP, focusing on their methodological
quality, using the Appraisal of Guidelines Research and
Evaluation II (AGREE II) instrument, and also assessed
the consistency of the CPG recommendations.
Methods
Search strategy and CPG selection
Two experienced systematic reviewers searched relevant
studies to identify CPGs for the management of NP. The
following electronic databases were searched: MEDLINE,
Embase, the National Guideline Clearinghouse, the
Guidelines International Network, and Canadian Medical
Association Infobase. Additionally, we searched the
websites of the related associations, institutes, soci-
eties, and communities, including EFNS, the Canadian
Pain Society, IASP, and the South African Society of
Anaesthesiologists.
The following terms and Boolean operators were used
in Mesh and free-text searches: (Practice Guideline OR
Guideline OR Consensus OR Recommendation) and
neuropathic pain. Finally, we also scanned the reference
lists of relevant published articles not identified in the
database searches.
Eligibility criteria
Two reviewers independently examined and selected
the CPGs according to inclusion and exclusion criteria.
The inclusion criteria were as follows: (1) explicit
statement identifying itself as a “guideline”; (2) CPGs
that included recommendations concerning screening,
diagnosis, and/or management for neuropathic pain;
(3) CPGs that included a systematic review of the evi-
dence; (4) CPGs produced by the related associations,
institute, societies, or communities; (5) CPGs pub-
lished in English. The exclusion criteria were as fol-
lows: (1) consensus statements, which were derived
from the collective opinion of an expert panel not
based on a systematic review of the evidence; (2) articles
including primary studies, narrative reviews, text-like doc-
uments on development methods, documents on com-
ments related to CPGs; (3) documents focused entirely on
a unique condition, such as cancer-related neuropathic
pain, postherpetic neuralgia, diabetic neuropathy, among
others.
Selection of CPGs
Following completion of all searches, references were
merged and duplicates were removed. By reading titles
and abstracts, two reviewers independently scanned
the references to verify their eligibility using the pre-
defined inclusion and exclusion criteria listed above.
Additionally, two reviewers independently scanned the
full-text to further verify their eligibility according to
the eligibility criteria after the full-text article was
obtained. If needed, disagreements were resolved by
discussion with a third reviewer.
Appraisal of selected CPGs using AGREE II instrument
The AGREE II instrument, an updated version of the
original AGREE instrument, is an international, rigor-
ously developed, and validated instrument used widely
to assess CPGs [25]. It consists of 23 key items organized
into six domains: “scope and purpose” (items 1–3),
“stakeholder involvement” (items 4–7), “rigor of de-
velopment” (items 8–14), “clarity of presentation”
(items 15–18), “applicability” (items 19–21), and “editorial
independence” (items 22–23). Each item in a domain is
scored from 1 (strongly disagree) to 7 (strongly agree). A
score of 1 (strongly disagree) should be given if there is no
relevant information on the AGREE II items or this infor-
mation is very poorly reported. A score of 7 (strongly
agree) should be assigned when the full criteria and con-
siderations articulated in User’s Manual have been met. A
score between 2 and 6 should be given if reporting infor-
mation does not meet the full criteria or considerations
relevant to the AGREE II item [26]. Three reviewers
assessed each included CPG independently and provided
their scores on the overall assessment. Item scores were
discussed and scoring discrepancies were solved by con-
sensus. The score for each domain was calculated as fol-
lows: (obtained score-minimal possible score)/(maximal
possible score-minimal possible score). As defined by
AGREE II, we considered a CPG as satisfactory if it scored
at least 50 % on all six domains [27].
Statistical analysis
Descriptive and statistical analyses were performed for
each domain of the AGREE II instrument. Inter-rater re-
liability within each domain was examined using the
intra-class correlation coefficient (ICC) with a 95 % con-
fidence interval. The degree of agreement was classified
according to the scale proposed by Landis and Koch, as
follows: poor (<0.00), slight (0.00–0.20), fair (0.21–0.40),
moderate (0.41–0.60), substantial (0.61–0.80) and very
good or almost perfect (0.81–1.00) [28]. All statistical
analyses were performed using SPSS and statistical sig-
nificance was considered with P < 0.05.
Results
Study selection
As shown in Fig. 1, the database search identified 1759
documents. After three reviewers read the title, ab-
stract and full-text according to the inclusion and ex-
clusion criteria, 16 articles were eventually selected
for inclusion.
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Characteristic of the CPGs
Table 1 shows the summary of the characteristics of
included CPGs. The sixteen CPGs were published be-
tween 2004 and 2014. Among the 16 included CPGs,
12 CPGs were original, and five were updated ver-
sions. With the exception of the CPGs published by
Latin American, South American, and Middle East re-
gions, all the included CPGs were developed using an
evidence-based approach. The 16 CPGs selected focused
on the assessment and pharmacological and interventional
treatments. In terms of funding, CPGs were financed in-
dependently by professional organizations, governments
and academic societies, except for one CPG developed in
Latin America that did not disclose a funding source. Of
the sixteen selected CPGs, ten CPGs were developed by
medical societies, four by governmental agencies, and two
by professional organizations (Additional files 1 and 2).
CPGs appraisal results using the AGREE-II instrument
Three reviewers evaluated the 16 included CPGs using
the AGREE II instrument. Table 2 summarizes the re-
sults of the scores for each CPG. None of the selected
CPGs performed satisfactorily, that is, none achieved
a score of greater than 50 % in all six AGREE II in-
strument domains. The highest score was obtained in
the “Clarity and Presentation” domain, followed by
the “Scope and Purpose”, “Editorial Independence”,
“Rigor of Development”, “Stakeholder Involvement”, and
“Applicability” domains. The lowest scores among all six
AGREE II domains were obtained for the “Applicability”
domain.
The results of the inter-rater reliability assessments
among the three reviewers are presented in Table 3.
Reliability of the assessment using the AGREE II instru-
ment showed high scores in general. With the exception
of Domain 4, classified as substantial, ICC score of the
remaining domains was graded as very good according
to the scale by Landis and Koch.
Recommendations of the CPGs
As shown in Table 4, we summarized the consensus treat-
ment recommendations. The anticonvulsants pregabalin
and gabapentin, low-dose TCAs, SSNRIs duloxetine and
venlafaxine, and topical lidocaine showed efficacy for the
management of NP and were recommended as first-line
and second-line medications, respectively.
Fig. 1 Selection process
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Table 1 Summary and characteristics of NP management guidelines included in the study
Guideline name Country or region Release time Developed methods Institute Update Clinical problem Funding
EFNS guidelines on neuropathic pain
assessment
European 2004 Evidence-based approach EFNS (European Federation of
Neurological Societies)
1 (2009) assessment EFNS
EFNS guidelines on pharmacological
treatment of neuropathic pain
European 2006 Evidence-based approach EFNS 1 (2010) pharmacological treatment EFNS
EFNS guidelines on neurostimulation
therapy for neuropathic pain
European 2007 Evidence-based approach EFNS 0 neurostimulation therapy EFNS
EFNS guidelines on neuropathic pain
assessment:revised 2009
European 2009 Evidence-based approach EFNS 0 assessment EFNS
EFNS guidelines on pharmacological
treatment of neuropathic pain:
2010 revision
European 2010 Evidence-based approach EFNS 0 pharmacological treatment EFNS
Pharmacological management
of chronic neuropathic pain -
Consensus statement and guidelines
from the canadian pain society
Canada 2007 Evidence-based approach
and Consensus statement
CPS 1 (2014) pharmacological treatment Pfizer Canada
Evidence-based guideline for
neuropathic pain interventional
treatments: spinal cord stimulation,
intravenous infusions, epidural
injections and nerve blocks
Canada 2012 Evidence-based approach CPS 0 Interventional treatments: spinal
cord stimulation, intravenous




chronic neuropathic pain: Revised
Consensus statement and guidelines
from the canadian pain society
Canada 2014 Evidence-based approach
and Consensus statement




International 2007 Evidence-based approach NeuPSIG 0 pharmacological treatment IASP NeuPSIG
NeuPSIG guidelines on neuropathic
pain assessment




International 2013 Evidence-based approach NeuPSIG 0 Interventional treatments IASP NeuPSIG
Pharmacological management of
neuropathic pain in non-specialist
settings: summary of NICE guidance
United Kindom 2010 Evidence-based approach NICE 1 (2013) pharmacological treatment NICE
Neuropathic pain – pharmacological
management: The pharmacological
management of neuropathic pain in
adults in non-specialist settings













Table 1 Summary and characteristics of NP management guidelines included in the study (Continued)
Clinical practice guidelines for
management of neuropathic pain:
Expert panel recommendations for
South Africa
South Africa 2012 Consensus statement painsa (Pain South Africa); NASA
(Neurological Association of South
Africa); PIRA (Pain Interventions
and Regional Anaesthesia); SASA
(South African Society of
Anaesthesiologists); SASCA
(South African Spinal Cord Association)
1 (2013) neuropathic management Pfize
Guidelines for the diagnosis and
management of neuropathic pain:
Consensus of a group of latin
american experts
Latin America 2009 Consensus statement FEDELAT (Latin American Federation
of Chapters of the International
Association for the Study of Pain)
0 neuropathic management not mention
Guidelines for the pharmacological
treatment of peripheral neuropathic
pain: Expert panel recommendations
for the middle east region
Middle East 2010 Consensus statement A multidisciplinary panel of Middle
East and international experts
0 pharmacological treatment Pfizer Inc














In the present study, we evaluated the quality of CPGs
and consistency of the recommendations of CPGs for
the management of NP to assist physicians in the selec-
tion of the appropriate recommendations. Our review
demonstrated that the overall quality of the CPGs based
on the AGREE II instrument was poor. However, we
found consistency in the recommendations stated in the
16 CPGs with respect to drug treatment.
The AGREE II instrument allows the evaluation of
various aspects of the guidelines, including integrity, re-
producibility, and transparency of guidelines among six
domains. Each domain has a different value and con-
cern. Domain 1, “Scope and Purpose,” is concerned with
the overall aim of the guideline, the specific health
questions being addressed, and the target population
(items 1–3). Domain 2, “Stakeholder Involvement,” fo-
cuses on the extent to which the guideline was developed
by the appropriate stakeholders and represents the views
of its intended users (items 4–6). Domain 3, “Rigor of
Development,” relates to the process used to gather
and synthesize the evidence, the methods to formu-
late the recommendations, and update them (items
7–14). Domain 4, “Clarity of Presentation,” deals with
the language, structure, and format of the guideline
(items 15–17). Domain 5, “Applicability” pertains to
the likely barriers and facilitators to implementation,
strategies to improve uptake, and resource implica-
tions of applying the guideline (items 18–21). Domain 6,
“Editorial Independence” is concerned with the formula-
tion of recommendations not being unduly biased with
competing interests (items 22–23).
Our study showed that four domains concerning
“Stakeholder Involvement”, “Rigor of Development”,
“Applicability”, and “Editorial Independence” had serious
shortcomings because the related information was poor
Table 3 Inter-class correlation coefficient for mean rater scores by AGREE domain
Domain Intraclass correlation coefficient
(95 % CI/average)
Cronbach’s alpha F value sig
Scope and purpose 0.857 (0.670–0.945) 0.96 25.3 0.000
Stakeholder involvement 0.899 (0.786–0.960) 0.96 26.3 0.000
Rigor of development 0.916 (0.680–0.974) 0.99 68.8 0.000
Clarity of presentation 0.704 (0.135–0.906) 0.97 30.3 0.000
Applicability 0.988 (0.974–0.996) 1 255.5 0.000
Editorial independence 0.977 (0.949–0.991) 0.99 137 0.000
Table 2 Domain scores of NP management guidelines according to the AGREE II
Domain 1 Domain 2 Domain 3 Domain 4 Domain 5 Domain 6
EFNS (2001)
EFNS (2004) 87 % 33 % 41 % 72 % 0 % 0 %
EFNS (2006) 87 % 41 % 67 % 87 % 0 % 60 %
EFNS (2007) 87 % 41 % 61 % 91 % 0 % 60 %
EFNS (2009) 87 % 43 % 52 % 89 % 14 % 0 %
EFNS (2010) 87 % 43 % 55 % 89 % 14 % 60 %
CPS (2007) 54 % 69 % 44 % 91 % 0 % 60 %
CPS (2012) 82 % 52 % 69 % 91 % 0 % 100 %
CPS (2014) 54 % 61 % 55 % 91 % 0 % 60 %
NeuPSIG (2007) 78 % 33 % 48 % 91 % 0 % 93 %
NeuPSIG (2011) 76 % 35 % 65 % 85 % 0 % 60 %
NeuPSIG (2013) 87 % 39 % 51 % 57 % 0 % 93 %
NICE (2010) 85 % 91 % 88 % 91 % 35 % 60 %
NICE (2013) 85 % 63 % 86 % 91 % 42 % 60 %
LA (2009) 76 % 35 % 38 % 52 % 33 % 0 %
ME (2010) 74 % 26 % 27 % 81 % 0 % 100 %
SA (2012) 76 % 48 % 28 % 81 % 1 % 63 %
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IASP (2007) CPS (2007) Latin Amercian
(2009)





Gabapentin Pregabalin Pregabalin Pregabalin Pregabalin Pregabalin Pregabalin
Pregabalin Gabapentin Gabapentin Gabapentin Gabapentin Gabapentin
TCAs Nortriptyline TCAs Nortriptyline Amitriptyline Nortriptyline Low-dose amitriptyline TCAs TCAs
Desipramine Desipramine Desipramine Other TCA
Amitriptyline
Topical treatments lidocaine patch
5 %
Topical lidocaine Topical lidocaine Topical lidocaine Topical lidocaine





SNRIs Venlafaxine Gabapentin Duloxetine Either increasing the
dose of the current
drug or adding a drug
from a different class.
For combination
treatment, pregabalin





Topical treatments Topical lidocaine








Opioid analgesics Tramadol Tramadol recommended
followed by strong
opioids, or combination
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provided. The remaining domains, including “Scope and
Purpose” and “Clarity of Presentation” tended to more
precisely reported because most of the included guide-
lines described in detail the specific and focused clinical
questions they aimed to address, the target population,
specific and unambiguous presentation, different man-
agement options for different presentations, and easily
identifiable presentation.
Although the AGREE II instrument provides six inde-
pendent domains, the “Rigor of Development” domain is
considered the strongest indicator of quality of all the
domains because it evaluates the integrity of the guide-
line development process. Among the included CPGs,
low scores in the “Rigor of Development” domain were
partly because of poor performance in this aspect, in-
cluding the literature search and selection methods, lack
of external review prior to publication, and lack of
guideline updating mechanisms. Among the six do-
mains, the quality of the “Applicability” domain also
plays a significant role. A guideline developed systemat-
ically with clear recommendations based on the best
available evidence could improve the healthcare practice
[2]. However, in the present study, most of included
guidelines did not describe facilitators and barriers to
their application, did not consider the potential resource
implications of applying the recommendations, and did
not present monitoring or auditing criteria; thus they
had a limited effect on improving healthcare quality
[2, 27]. Especially for CPGs published by developing
regions, treatment recommendations were restricted
by the limited availability of resources faced in the re-
spective regions. The “Applicability” domain had a
great effect on the implementation of CPGs. Addition-
ally, the “Editorial Independence” domain refers to the
most frequent sources of bias in the guidelines, and it
was also found to be poor among the CPGs assessed
in this study. Although the authors of guidelines might
have economic ties with the pharmaceutical industry
or even funding from pharmaceutical companies, most
guidelines fail to provide information about potential
conflicts of interest.
Guidelines need to be evaluated not only for methodo-
logical quality but also for validity of their content in
terms of recommendations. Thus, this study also analyzed
the recommendations of these guidelines for the manage-
ment of NP. In general, these recommendations were con-
sistent on the diagnosis, assessment and pharmacological
management despite scoring poorly in their rigor of devel-
opment. It was difficult to tell whether we obtained these
results because there was insufficient evidence to develop
the guidelines or because the CPG authors did not search
and make use of the best evidence available.
A large number of the drug development research has
been devoted to the field of NP. A large number of
analgesic agents have shown efficacy for the treatment
of NP. However, no more than 40–60 % of patients have
obtained sufficient pain relief with medications alone and
in combination [11, 17]. Thus, it should be noted that
treatment of patients with NP should be considered an in-
tegral component of a more comprehensive approach.
In general, the guidelines for the management of NP
vary considerably in terms of quality, because of the
apparently low standards. To reduce the variability of
the CPGs, guideline development groups should have
standard methodology and strategy. Further, it would be
helpful to become familiarized with the AGREE II in-
strument domains to know what information should be
reported and how it ought to be reported in the CPGs.
Here, we also give some pointers to reduce the vari-
ability among the CPGs:
1) The study should describe the specific health ques-
tion it aims to address, such as prevention, screening,
diagnosis, or treatment, and target population, including
sex, age clinical condition, severity stage of the disease,
comorbidities, and others. 2) The guideline development
group should include individuals from all relevant pro-
fessional groups, not only or mainly health care pro-
viders. Competing interests of guideline development
group members should be fully recorded and addressed.
3) In the guideline development process, appropriate
methodologies and rigorous strategies are important for
successful implementation of the resulting recommenda-
tions, such as the systematic methods and criteria for
selecting the evidence, methods for formulating the rec-
ommendations, health benefits, side effects considered
in formulating the recommendations, links between the
recommendations and the evidence. Additionally, guide-
lines should be externally reviewed prior to their publi-
cation, and a procedure for guideline updating should be
planned and described. 4) The different options for the
management of the condition or health issue should be
clearly presented and the recommendations should be
specific and unambiguous. 5) The views of the funding
body and interests of the development group should
been recorded and addressed.
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